ERIC STRAIN

Summary

Publications

  1. ncbi request reprint Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial
    E C Strain
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    JAMA 281:1000-5. 1999
  2. ncbi request reprint Relative bioavailability of different buprenorphine formulations under chronic dosing conditions
    Eric C Strain
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Drug Alcohol Depend 74:37-43. 2004
  3. ncbi request reprint Single versus multiple drug focus in substance abuse clinical trials research: the devil is in the details
    Eric C Strain
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Drug Alcohol Depend 70:131-4. 2003
  4. ncbi request reprint Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients
    Eric C Strain
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Clin J Pain 18:S14-27. 2002
  5. ncbi request reprint Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine
    Eric C Strain
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 159:161-6. 2002
  6. ncbi request reprint Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers
    E C Strain
    Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 148:374-83. 2000
  7. ncbi request reprint HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone
    David C Lott
    Chemical Dependency Program, Linden Oaks Hospital at Edward, 825 S West St, Naperville, IL 60540, USA
    J Subst Abuse Treat 31:187-94. 2006
  8. ncbi request reprint Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans
    C Patrick Carroll
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Exp Clin Psychopharmacol 14:109-20. 2006
  9. ncbi request reprint Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period
    Christopher J Correia
    Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 189:297-306. 2006
  10. ncbi request reprint Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence
    Lisa A Marsch
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Exp Clin Psychopharmacol 13:293-302. 2005

Detail Information

Publications28

  1. ncbi request reprint Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial
    E C Strain
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    JAMA 281:1000-5. 1999
    ..However, despite recommendations regarding effective dosing of methadone, controlled clinical trials of higher-dose methadone have not been conducted...
  2. ncbi request reprint Relative bioavailability of different buprenorphine formulations under chronic dosing conditions
    Eric C Strain
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Drug Alcohol Depend 74:37-43. 2004
    ..This study compared the relative buprenorphine bioavailability of these different formulations...
  3. ncbi request reprint Single versus multiple drug focus in substance abuse clinical trials research: the devil is in the details
    Eric C Strain
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Drug Alcohol Depend 70:131-4. 2003
  4. ncbi request reprint Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients
    Eric C Strain
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Clin J Pain 18:S14-27. 2002
    ..The presence of a pain condition can further complicate assessment and treatment, as either pain itself or treatments used for pain may produce symptoms that overlap with psychiatric disorders...
  5. ncbi request reprint Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine
    Eric C Strain
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 159:161-6. 2002
    ..Naloxone has been combined with buprenorphine to decrease the parenteral abuse potential of buprenorphine. This addition of naloxone may also confer further opioid blockade efficacy...
  6. ncbi request reprint Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers
    E C Strain
    Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 148:374-83. 2000
    ..Non-parenteral abuse of opioids such as buprenorphine may be more likely in people who have less severe substance abuse disorders (e.g., are not physically dependent upon opioids)...
  7. ncbi request reprint HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone
    David C Lott
    Chemical Dependency Program, Linden Oaks Hospital at Edward, 825 S West St, Naperville, IL 60540, USA
    J Subst Abuse Treat 31:187-94. 2006
    ..These results demonstrate that all three medications can be highly effective in decreasing HIV risk behaviors when the dose is optimized. Reductions in sexual behaviors for the METH group are consistent with known METH side effects...
  8. ncbi request reprint Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans
    C Patrick Carroll
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Exp Clin Psychopharmacol 14:109-20. 2006
    ..In contrast, tramadol's pattern of effects was more similar to that of hydromorphone and suggestive of mild opioid-agonist effects (withdrawal suppression), though not to a statistically significant degree...
  9. ncbi request reprint Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period
    Christopher J Correia
    Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 189:297-306. 2006
    ..Buprenorphine has a long duration of action that allows less than daily dosing for opioid dependence, but pharmacologic characterization of buprenorphine's duration of effects over multiple days is incomplete...
  10. ncbi request reprint Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence
    Lisa A Marsch
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Exp Clin Psychopharmacol 13:293-302. 2005
    ..We did not find any factors that would strongly guide selection of one medication over others...
  11. ncbi request reprint Characteristics of older opioid maintenance patients
    Michelle R Lofwall
    Johns Hopkins University School of Medicine Behavioral Pharmacology Research Unit and Addiction Treatment Services, Baltimore, MD 21224, USA
    J Subst Abuse Treat 28:265-72. 2005
    ..Low rates of positive urine opioid tests occurred for both older and younger patients without age-specific services...
  12. pmc Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone
    James Rosado
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Drug Alcohol Depend 90:261-9. 2007
    ..Acute doses of buprenorphine can precipitate withdrawal in opioid dependent persons. The likelihood of this withdrawal increases as a function of the level of physical dependence...
  13. ncbi request reprint A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers
    Miriam Z Mintzer
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Drug Alcohol Depend 74:205-9. 2004
    ..Future studies incorporating larger sample sizes and non-drug controls, as well as directly comparing buprenorphine to methadone and LAAM are needed to further test the hypothesis of limited impairment with buprenorphine...
  14. ncbi request reprint Modest opioid withdrawal suppression efficacy of oral tramadol in humans
    Michelle R Lofwall
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Psychopharmacology (Berl) 194:381-93. 2007
    ..Tramadol is in an unscheduled atypical analgesic with low rates of diversion and abuse and mixed pharmacologic actions, including modest opioid agonist activity...
  15. ncbi request reprint Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans
    Sharon L Walsh
    Behavioral Pharmacology Research Unit, Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD 21224, USA
    Addiction 98:427-39. 2003
    ..To examine the efficacy of lofexidine, an alpha2 adrenergic agonist, to suppress opioid withdrawal symptoms in opioid-dependent humans under in-patient laboratory conditions by using a naloxone challenge procedure...
  16. ncbi request reprint Buprenorphine for postoperative pain following general surgery in a buprenorphine-maintained patient
    Sarah W Book
    Am J Psychiatry 164:979. 2007
  17. pmc Comparison of demographic and clinical characteristics between opioid-dependent individuals admitted to a community-based treatment setting and those enrolled in a research-based treatment setting
    C Patrick Carroll
    Addiction Treatment Services, Johns Hopkins Bayview Medical Center, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
    J Subst Abuse Treat 33:355-61. 2007
    ..Interestingly, many of these differences were strongest in women as compared with men...
  18. ncbi request reprint Simultaneous determination of buprenorphine, norbuprenorphine and the enantiomers of methadone and its metabolite (EDDP) in human plasma by liquid chromatography/mass spectrometry
    Maria Esther Rodriguez-Rosas
    Bioanalytical and Drug Discovery Unit, Gerontology Research Center, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Drive, Baltimore, MD 21224 6825, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 850:538-43. 2007
    ..5% and for accuracy was <4.0%. The method was validated and used to analyze plasma samples obtained from opioid dependent methadone-maintained adults enrolled in a research study...
  19. ncbi request reprint Treatment of patients with substance use disorders, second edition. American Psychiatric Association
    Herbert D Kleber
    Am J Psychiatry 164:5-123. 2007
  20. ncbi request reprint Treatment of patients with substance use disorders, second edition. American Psychiatic Association
    Herbert D Kleber
    Am J Psychiatry 163:5-82. 2006
  21. ncbi request reprint Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report
    Charles Grudzinskas
    NDA Partners LLC, 720 Riverview Terrace, Annapolis, MD 21401, USA
    Drug Alcohol Depend 83:S77-82. 2006
    ..Finally, knowledge and experience are needed to translate scientific work into a predictable, transparent and reliable regulatory process...
  22. ncbi request reprint Decreased frontal white-matter volume in chronic substance abuse
    Thomas E Schlaepfer
    Department of Psychiatry, University Hospital, Bonn, Germany
    Int J Neuropsychopharmacol 9:147-53. 2006
    ....
  23. ncbi request reprint Safety and efficacy of L-tryptophan and behavioral incentives for treatment of cocaine dependence: a randomized clinical trial
    Hendree E Jones
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Am J Addict 13:421-37. 2004
    ..This study also showed that contingent vouchers were effective in the novel experimental model of relapse prevention...
  24. ncbi request reprint [Brazilian guideline for the treatment of patients with opioids dependence syndrome]
    Danilo Antonio Baltieri
    Departamento de Dependência Química, Associação Brasileira de Psiquiatria, Brazil
    Rev Bras Psiquiatr 26:259-69. 2004
    ..Also, the essential historical, epidemiological and neurobiological aspects of opioid dependence are reviewed...
  25. ncbi request reprint A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies
    David E Moody
    Center for Human Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    Anal Biochem 306:31-9. 2002
    ..These results suggest this method is suitable for both in vivo and in vitro studies of buprenorphine metabolism to norbuprenorphine...
  26. pmc Outpatient treatment entry and health care utilization after a combined medical/substance abuse intervention for hospitalized medical patients
    THOMAS P O'TOOLE
    Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
    J Gen Intern Med 17:334-40. 2002
    ..Drug-abusing patients utilize extensive amounts of health services resources, yet the acute medical hospitalization has typically not been used effectively to engage patients in substance abuse treatment...
  27. ncbi request reprint Voucher-based reinforcement of opiate abstinence during methadone detoxification
    Elias Robles
    Department of Pharmacology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Drug Alcohol Depend 65:179-89. 2002
    ..Voucher-based reinforcement procedures could be useful for successfully transitioning patients into opiate antagonist therapy, or drug-free treatments...
  28. ncbi request reprint Experimentally-induced spontaneous opiate withdrawal: relationship to cigarette craving and expired air carbon monoxide
    Michelle R Lofwall
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Addict 16:310-5. 2007
    ..Interestingly, craving was only reduced for items related to the positive reinforcing effects of smoking. These preliminary results suggest that OW may be a favorable context to initiate smoking cessation treatment interventions...

Research Grants35

  1. Medications Development for Drug Abuse Disorders
    Eric C Strain; Fiscal Year: 2010
    ..This is a residential controlled clinical trial that will test the efficacy and safety of tramadol compared to clonidine and buprenorphine in the treatment of opioid withdrawal. ..
  2. SEROTONIN Treatment of Cocaine Dependence
    ERIC STRAIN; Fiscal Year: 2005
    ....
  3. CLINICAL RESEARCH ON DRUG ABUSE
    ERIC STRAIN; Fiscal Year: 2006
    ..The applicant is Eric Strain, a physician-researcher in the Department of Psychiatry at Johns Hopkins University School of Medicine. Dr...
  4. Mentoring of Clinical Investigators in Patient Oriented Research
    ERIC STRAIN; Fiscal Year: 2007
    ..The applicant is Eric Strain, a physician-researcher in the Department of Psychiatry at Johns Hopkins University School of Medicine. Dr...
  5. Medications Development for Drug Abuse Disorders
    ERIC STRAIN; Fiscal Year: 2007
    ..abstract_text> ..
  6. EVALUATION OF OPIOID ANTAGONIST ACTIVITY IN HUMANS
    ERIC STRAIN; Fiscal Year: 2007
    ....
  7. EVALUATION OF OPIOID ANTAGONIST ACTIVITY IN HUMANS
    ERIC STRAIN; Fiscal Year: 2009
    ....
  8. EVALUATION OF OPIOID ANTAGONIST ACTIVITY IN HUMANS
    Eric C Strain; Fiscal Year: 2010
    ....
  9. EVALUATION OF OPIOID ANTAGONIST ACTIVITY IN HUMANS
    ERIC STRAIN; Fiscal Year: 1999
    ....
  10. TRYPTOPHAN AND BEHAVIOR THERAPY FOR COCAINE ABUSE
    ERIC STRAIN; Fiscal Year: 1999
    ....